Log in

Relevant bibliographies by topics / MERCAPTOPURINA / Journal articles

Journal articles on the topic 'MERCAPTOPURINA'

To see the other types of publications on this topic, follow the link: MERCAPTOPURINA.

Author: Grafiati

Published: 11 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'MERCAPTOPURINA.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Bermejo, F., A. López-Sanromán, A. Algaba, M. Van Domselaar, J. P. Gisbert, J. A. Carneros, E. Garrido, M. P. Valer, M. Rodríguez-Gandía, and B. Piqueras. "Rescate con mercaptopurina en pacientes con hepatotoxicidad por azatioprina." Gastroenterología y Hepatología 32, no. 3 (March 2009): 225. http://dx.doi.org/10.1016/j.gastrohep.2009.01.100.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Chávez Espinoza, Fermín, José Eguren Cáceres, Rómulo Barrionuevo Calderón, Roberto Rodríguez Luna, Américo Mayorga C., Moisés Núñez P., Luis Fernán Zegarra, and Raúl Velásquez del C. "Algunas consideraciones acerca del coriocarcinoma en el Hospital General de Arequipa." Revista Peruana de Ginecología y Obstetricia 11, no. 3 (July 9, 2015): 267–84. http://dx.doi.org/10.31403/rpgo.v11i1273.

Full text

Abstract:

Cinco casos de coriocarcinoma y 101 de la mola hidatiforme se produjeron entre 1961 y 1964; esto significa una alta incidencia de tumores coriónicas comparable a la registrada en Hong Kong, Filipinas y Japón. AII los cinco casos tuvo tratamiento quirúrgico y un caso también recibió 6-mercaptopurina. Un comentario sobre la etiología, la inmunología, la edad y la historia obstétrica de los pacientes se hacen.

APA, Harvard, Vancouver, ISO, and other styles

3

Cabré, E. "Indicaciones de la azatioprina (o 6-mercaptopurina) en la enfermedad inflamatoria intestinal." Gastroenterología y Hepatología 25, no. 5 (January 2002): 319–26. http://dx.doi.org/10.1016/s0210-5705(02)79028-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Martín-Ezquerra, Gemma, Jesús Molinero-Caturla, and P. a. u. Umbert-Millet. "Quistes miliares en placa en las extremidades. Posible toxicodermia por 6-mercaptopurina." Actas Dermo-Sifiliográficas 95, no. 7 (January 2004): 449–50. http://dx.doi.org/10.1016/s0001-7310(04)76856-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Martí, Nuria, and Esperanza Jordá. "Erupción acneiforme tras retirada de 6-mercaptopurina y metotrexato en una niña con leucemia." Piel 26, no. 8 (October 2011): 424–25. http://dx.doi.org/10.1016/j.piel.2011.03.013.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Payeras Capó, M. A., A. Escarda Gelabert, A. Erimeiku Barahona, I. Pérez Medrano, E. Antón Valentí, and D. Ginard Vicens. "Hiperplasia nodular regenerativa: hepatotoxicidad por 6-mercaptopurina en un paciente con enfermedad de Crohn." Enfermedad Inflamatoria Intestinal al Día 16, no. 2 (May 2017): 84–86. http://dx.doi.org/10.1016/j.eii.2016.12.008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Bastida Paz, Guillermo, Pilar Nos Mateu, Mariam Aguas Peris, Belén Beltrán Niclós, María Rodríguez Soler, and Julio Ponce García. "Optimización del tratamiento inmunomodulador con azatioprina o 6-mercaptopurina en pacientes con enfermedad inflamatoria intestinal." Gastroenterología y Hepatología 30, no. 9 (October 2007): 511–17. http://dx.doi.org/10.1157/13111681.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Gisbert, J. P., P. M. Linares, A. G. McNicholl, J. Maté, and F. Gomollón. "EFICACIA DE LA AZATIOPRINA Y LA MERCAPTOPURINA EN LA COLITIS ULCEROSA. REVISIÓN SISTEMÁTICA Y METAANÁLISIS." Gastroenterología y Hepatología 32, no. 3 (March 2009): 213–14. http://dx.doi.org/10.1016/j.gastrohep.2009.01.075.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Franco, Gabriele Alvernaz Silva, Liliane Faria da Silva, Flavio Luiz Seixas, Fernanda Garcia Bezerra Góes, and Emília Gallindo Cursino. "Orientações para o cuidado domiciliar de crianças e adolescentes em quimioterapia antineoplásica oral." Research, Society and Development 10, no. 4 (April 16, 2021): e40310414530. http://dx.doi.org/10.33448/rsd-v10i4.14530.

Full text

Abstract:

Objetivos: Identificar os quimioterápicos antineoplásicos orais mais utilizados pelas crianças e adolescentes em tratamento ambulatorial; e descrever, a partir da literatura científica, as principais orientações para os cuidados domiciliares às crianças e adolescentes que usam quimioterápicos antineoplásicos orais. Método: Estudo descritivo, realizado em um hospital federal na cidade do Rio de Janeiro, Brasil. Foram analisados os prontuários de 45 crianças e adolescentes em tratamento com quimioterápicos orais, no período de julho a setembro de 2020. Resultados: Os quimioterápicos utilizados foram: mercaptopurina (29,1%), metrotexato (21%), imatinibe (19,3%), temozolamida (9,7%), everolimus (8,1%), ciclofosfamida (6,4%), tioguanina (1,6%), etoposideo (1,6%), topotecano (1,6%) e pazopanibe (1,6%). Assim, para cada quimioterápico, foram elencadas as principais orientações para os cuidados domiciliares às crianças e adolescentes em uso deles. Considerações finais: O estudo possibilita direcionamento das ações de orientação para o cuidado domiciliar de crianças e adolescentes em quimioterapia antineoplásica oral visando à adesão e maior segurança no tratamento.

APA, Harvard, Vancouver, ISO, and other styles

10

ASSUMPÇÃO, Izaura Ramos, Maraci RODRIGUES, and Dorina BARBIERI. "Tratamento da retocolite ulcerativa inespecífica em criança com enemas contendo butirato: relato de caso." Arquivos de Gastroenterologia 36, no. 4 (December 1999): 238–43. http://dx.doi.org/10.1590/s0004-28031999000400012.

Full text

Abstract:

Objetivo - Chamar a atenção para uma promissora alternativa terapêutica no tratamento de retocolite ulcerativa inespecífica em crianças. Método -- É descrito o caso de uma criança com diagnóstico de retocolite ulcerativa inespecífica, com forma evolutiva crônica contínua, refratária ao tratamento convencional e que foi tratada com enemas contendo butirato. Revisão de literatura pertinente ao caso foi realizada. Resultados - Paciente de 4 anos, feminina, parda, com diagnóstico de retocolite ulcerativa inespecífica desde 1 ano de idade e evolução refratária ao tratamento com corticóide (via oral e retal) e imunossupressor (6-mercaptopurina). Respondeu de modo satisfatório com melhora do quadro clínico, laboratorial, endoscópico e histológico, após o uso de enemas com butirato semelhante às descrições da literatura internacional. Conclusão - Embora sem estar esclarecido o mecanismo de ação do butirato na retocolite ulcerativa inespecífica, melhora significante foi observada neste caso, acenando como possibilidade terapêutica segura nos casos de retocolite ulcerativa inespecífica confinados a segmentos distais.

APA, Harvard, Vancouver, ISO, and other styles

11

Álvarez Delgado, A., M. L. Pérez García, P. M. Fradejas Salazar, C. de la Coba Ortíz, and A. Rodríguez Pérez. "Cáncer de Cérvix invasivo en paciente en tratamiento crónico con 6-mercaptopurina por enfermedad de Crohn." Gastroenterología y Hepatología 26, no. 1 (January 2003): 52–53. http://dx.doi.org/10.1157/13042216.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

De La Coba Ortiz, C., A. Álvarez Delgado, M. L. Pérez garcía, P. M. Fradejas salazar, and A. Rodríguez Pérez. "Cáncer de cérvix invasivo en paciente en tratamiento crónico con 6-mercaptopurina por enfermedad de crohn." Gastroenterología y Hepatología 26, no. 1 (January 2003): 52–53. http://dx.doi.org/10.1016/s0210-5705(03)70342-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Gisbert, J. P., F. Gomollón, J. Maté, and J. M. Pajares. "Terapia individualizada con azatioprina o 6-mercaptopurina mediante monitorización de la actividad de la tiopurina metiltransferasa (TPMT)." Revista Clínica Española 202, no. 10 (January 2002): 555–62. http://dx.doi.org/10.1016/s0014-2565(02)71143-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Ayad .A. Mohamed, Janan G. Hassan*,. "Asymptomatic hypoglycemia among children with acute lymphoblastic leukemia on maintenance therapy." Innovative Journal of Medical and Health Science 9, no. 1 (February 4, 2019): 242–46. http://dx.doi.org/10.15520/ijmhs.v9i1.2430.

Full text

Abstract:

Background: Knowledge of the adverse effects of maintenance chemotherapy , therapy in children with acute lymphoblastic leukemia being treated according to the MRC modified protocols. Objective: To figure out the asymptomatic hypoglycemia in a sample of children patients at a stage of maintenance therapy. Methods: Prospective study was carried out over 6 months from the 1st of January 2004 till the 30th of June 2004. A total sample of 30 patients aged between (1 and 15 years) with acute lymphoblastic leukemia were included in study who were treated at Basra Maternity and child teaching hospital, all of them were being treated according to MRC modified protocol and on maintenance therapy (6 mercaptopurina + methotroxate), 35 healthy children matched for age and sex randomly selected as control. Results: Hypoglycemia were seen is 18 (60%) of patients with leukemia, 10 (55.5%) females and 8 (44.4%) males. Blood glucose level <3.33 mmol/L during 12 hours of overnight fasting. Conclusion: Hypoglycemia is the most common adverse effect in children with acute lymphoblastic leukemia on maintenance therapy.

APA, Harvard, Vancouver, ISO, and other styles

15

Milosevic, Goran, Nikola Kotur, Nada Krstovski, Jelena Lazic, Branka Zukic, Biljana Stankovic, Dragana Janic, et al. "Variants in TPMT, ITPA, ABCC4 And ABCB1 Genes as Predictors of 6-Mercaptopurine Induced Toxicity in Children with Acute Lymphoblastic Leukemia." Journal of Medical Biochemistry 37, no. 3 (July 1, 2018): 320–27. http://dx.doi.org/10.1515/jomb-2017-0060.

Full text

Abstract:

SummaryAcute lymphoblastic leukemia is the most common childhood malignancy. Optimal use of anti leukemic drugs has led to less toxicity and adverse reactions, and a higher survival rate. Thiopurine drugs, including 6-mercaptopurine, are mostly used as antileukemic medications in the maintenance phase of treatment for children with acute lymphoblastic leukemia. For those patients, TPMT genotype- tailored 6-mercaptopurine therapy is already implemented in the treatment protocols. We investigated the role of TPMT, ITPA, ABCC4 and ABCB1 genetic variants as predictors of outcome and 6-mercaptopurine induced toxicity during the maintenance phase of treatment in pediatric acute lymphoblastic leukemia. Sixty-eight children with acute lymphoblastic leukemia were enrolled in this study. Patients have been treated according to ALL IC-BFM 2002 or ALL IC-BFM 2009 protocols. Toxicity and adverse events have been monitored via surrogate markers (off-therapy weeks, episodes of leu - ko penia and average 6-mercaptopurine dose) and a prob- abilistic model was employed to predict overall 6-mercaptopurine related toxicity. We confirmed that patients with acute lymphoblastic leukemia that carry inactive TPMT allele(s) require 6- mercaptopurine dose reduction. ITPA and ABCC4 genetic variants failed to show an association with 6-mercapto - purine induced toxicity during the maintenance phase. Carriers of ABCB1 variant allele experienced greater hepatotoxicity. The probabilistic model Neural net which considered all the analysed genetic variants was assessed to be the best prediction model. It was able to discriminate ALL patients with good and poor 6-mercaptopurin tolerance in 71% of cases (AUC=0.71). This study contributes to the design of a panel of pharmacogenetic markers for predicting thiopurineinduced toxicity in pediatric ALL.

APA, Harvard, Vancouver, ISO, and other styles

16

García López, Santiago. "Si un paciente con enfermedad de Crohn se mantiene en remisión 4 años con azatioprina (o mercaptopurina), ¿debemos suspenderla?" Gastroenterología y Hepatología 31, no. 10 (December 2008): 704–5. http://dx.doi.org/10.1016/s0210-5705(08)75821-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Mohos, Violetta, Attila Pánovics, Eszter Fliszár-Nyúl, Gabriella Schilli, Csaba Hetényi, Přemysl Mladěnka, Paul W. Needs, Paul A. Kroon, Gábor Pethő, and Miklós Poór. "Inhibitory Effects of Quercetin and Its Human and Microbial Metabolites on Xanthine Oxidase Enzyme." International Journal of Molecular Sciences 20, no. 11 (May 31, 2019): 2681. http://dx.doi.org/10.3390/ijms20112681.

Full text

Abstract:

Quercetin is an abundant flavonoid in nature and is used in several dietary supplements. Although quercetin is extensively metabolized by human enzymes and the colonic microflora, we have only few data regarding the pharmacokinetic interactions of its metabolites. Therefore, we investigated the interaction of human and microbial metabolites of quercetin with the xanthine oxidase enzyme. Inhibitory effects of five conjugates and 23 microbial metabolites were examined with 6-mercaptopurine and xanthine substrates (both at 5 μM), employing allopurinol as a positive control. Quercetin-3′-sulfate, isorhamnetin, tamarixetin, and pyrogallol proved to be strong inhibitors of xanthine oxidase. Sulfate and methyl conjugates were similarly strong inhibitors of both 6-mercaptopurine and xanthine oxidations (IC50 = 0.2–0.7 μM); however, pyrogallol inhibited xanthine oxidation (IC50 = 1.8 μM) with higher potency vs. 6-MP oxidation (IC50 = 10.1 μM). Sulfate and methyl conjugates were approximately ten-fold stronger inhibitors (IC50 = 0.2–0.6 μM) of 6-mercaptopurine oxidation than allopurinol (IC50 = 7.0 μM), and induced more potent inhibition compared to quercetin (IC50 = 1.4 μM). These observations highlight that some quercetin metabolites can exert similar or even a stronger inhibitory effect on xanthine oxidase than the parent compound, which may lead to the development of quercetin–drug interactions (e.g., with 6-mercaptopurin or azathioprine).

APA, Harvard, Vancouver, ISO, and other styles

18

Gisbert, Javier P., Marta Luna, José Maté, Luis González-Guijarro, Carlos Cara, and José María Pajaresa. "Actividad de la tiopurina metiltransferasa y mielotoxicidad debida a azatioprina y 6-mercaptopurina en pacientes con enfermedad inflamatoria del intestino." Medicina Clínica 121, no. 1 (January 2003): 1–5. http://dx.doi.org/10.1016/s0025-7753(03)74110-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Gisbert, J. P., J. Maté, J. M. Pajares, and F. Gomollón. "Preguntas y respuestas sobre el papel de la azatioprina y la 6-mercaptopurina en el tratamiento de la enfermedad inflamatoria intestinal." Gastroenterología y Hepatología 25, no. 6 (January 2002): 401–15. http://dx.doi.org/10.1016/s0210-5705(02)70275-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Miron, T., F. Arditti, L. Konstantinovski, A. Rabinkov, D. Mirelman, A. Berrebi, and M. Wilchek. "Novel derivatives of 6-mercaptopurine: Synthesis, characterization and antiproliferative activities of S-allylthio-mercaptopurines." European Journal of Medicinal Chemistry 44, no. 2 (February 2009): 541–50. http://dx.doi.org/10.1016/j.ejmech.2008.03.027.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Tu, Chang Qing, and Xin Rong Wen. "Spectrophotometric Determination of 6-Mercaptopurine in Pharmaceutical Sample Using Fe(III)-Potassium Ferricyanide System." Advanced Materials Research 881-883 (January 2014): 479–83. http://dx.doi.org/10.4028/www.scientific.net/amr.881-883.479.

Full text

Abstract:

In the present work,we developed a simple,fast,sensitive and inexpensive method to determine 6-mercaptopurine (6-MP) in pharmaceutical sample using Fe (III)-potassium ferricyanide system by spectrophotometry.The results show that in acid medium, Fe (Ш) can be reduced to Fe (II) by hydrosulfuryl (-SH) in 6-Mercaptopurin molecule, and then Fe (II) reacts with potassium ferricyanide to form a soluble Prussian blue (KFeIII[FeII(CN)6]),the content of 6-MP was determinated indirectly through determinating the absorbance of the soluble Prussian blue.The various effect factors on the determination of 6-MP by spectrophotometry using potassium Fe (III)-ferricyanide system were investigated in detail.The maximum absorption wavelength of chromogenic system was 755 nm, good linear relationship was obtained between the absorbance and the concentration of 6-MP in the range of 0.4120~2.884 μ g·/mL,the equation of the linear regression was A=0.0411+0.1462C (μ g·/mL),with a linear correlation coefficient was 0.9991.This proposed method had been successfully applied to determinate of 6-MP in real pharmaceutical,and the results agreed well with those obtained by pharmacopoeial method.

APA, Harvard, Vancouver, ISO, and other styles

22

&NA;. "Mercaptopurine." Reactions Weekly &NA;, no. 1385 (January 2012): 29. http://dx.doi.org/10.2165/00128415-201213850-00104.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

&NA;. "Mercaptopurine." Reactions Weekly &NA;, no. 1397 (April 2012): 22–23. http://dx.doi.org/10.2165/00128415-201213970-00076.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

&NA;. "Mercaptopurine." Reactions Weekly &NA;, no. 723 (October 1998): 10. http://dx.doi.org/10.2165/00128415-199807230-00033.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

&NA;. "Mercaptopurine." Reactions Weekly &NA;, no. 1196 (April 2008): 29. http://dx.doi.org/10.2165/00128415-200811960-00088.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

&NA;. "Mercaptopurine." Reactions Weekly &NA;, no. 1121 (September 2006): 19. http://dx.doi.org/10.2165/00128415-200611210-00064.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

&NA;. "Mercaptopurine." Reactions Weekly &NA;, no. 1127 (November 2006): 17. http://dx.doi.org/10.2165/00128415-200611270-00054.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

&NA;. "Mercaptopurine." Reactions Weekly &NA;, no. 1153 (May 2007): 20. http://dx.doi.org/10.2165/00128415-200711530-00063.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

&NA;. "Mercaptopurine." Reactions Weekly &NA;, no. 1355 (June 2011): 22–23. http://dx.doi.org/10.2165/00128415-201113550-00072.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

&NA;. "Mercaptopurine." Reactions Weekly &NA;, no. 1359 (July 2011): 25–26. http://dx.doi.org/10.2165/00128415-201113590-00098.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

&NA;. "Mercaptopurine." Reactions Weekly &NA;, no. 1367 (September 2011): 28. http://dx.doi.org/10.2165/00128415-201113670-00095.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

&NA;. "Mercaptopurine." Reactions Weekly &NA;, no. 574 (October 1995): 9. http://dx.doi.org/10.2165/00128415-199505740-00026.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

&NA;. "Mercaptopurine." Reactions Weekly &NA;, no. 427 (November 1992): 10. http://dx.doi.org/10.2165/00128415-199204270-00038.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

&NA;. "Mercaptopurine." Reactions Weekly &NA;, no. 435 (January 1993): 9. http://dx.doi.org/10.2165/00128415-199304350-00043.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

&NA;. "Mercaptopurine." Reactions Weekly &NA;, no. 676 (November 1997): 9–10. http://dx.doi.org/10.2165/00128415-199706760-00024.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

&NA;. "Mercaptopurine." Reactions Weekly &NA;, no. 807 (June 2000): 10. http://dx.doi.org/10.2165/00128415-200008070-00028.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

&NA;. "Mercaptopurine." Reactions Weekly &NA;, no. 1400 (May 2012): 28. http://dx.doi.org/10.2165/00128415-201214000-00107.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

&NA;. "Mercaptopurine." Reactions Weekly &NA;, no. 1410 (July 2012): 30. http://dx.doi.org/10.2165/00128415-201214100-00096.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

&NA;. "Mercaptopurine." Reactions Weekly &NA;, no. 1414 (August 2012): 34–35. http://dx.doi.org/10.2165/00128415-201214140-00112.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

&NA;. "Mercaptopurine." Reactions Weekly &NA;, no. 373 (October 1991): 10. http://dx.doi.org/10.2165/00128415-199103730-00054.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

&NA;. "Mercaptopurine." Reactions Weekly &NA;, no. 1087 (February 2006): 19. http://dx.doi.org/10.2165/00128415-200610870-00064.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

&NA;. "Mercaptopurine." Reactions Weekly &NA;, no. 929 (November 2002): 9. http://dx.doi.org/10.2165/00128415-200209290-00029.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

&NA;. "Mercaptopurine." Reactions Weekly &NA;, no. 1231 (December 2008): 19. http://dx.doi.org/10.2165/00128415-200812310-00056.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

&NA;. "Mercaptopurine." Reactions Weekly &NA;, no. 297 (April 1990): 9. http://dx.doi.org/10.2165/00128415-199002970-00042.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

&NA;. "Mercaptopurine." Reactions Weekly &NA;, no. 320 (September 1990): 8. http://dx.doi.org/10.2165/00128415-199003200-00036.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

&NA;. "Mercaptopurine." Reactions Weekly &NA;, no. 1315 (August 2010): 32–33. http://dx.doi.org/10.2165/00128415-201013150-00103.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

&NA;. "Mercaptopurine." Reactions Weekly &NA;, no. 1316 (August 2010): 32. http://dx.doi.org/10.2165/00128415-201013160-00106.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

&NA;. "Mercaptopurine." Reactions Weekly &NA;, no. 1322 (October 2010): 21. http://dx.doi.org/10.2165/00128415-201013220-00071.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

&NA;. "Mercaptopurine." Reactions Weekly &NA;, no. 1324 (October 2010): 26. http://dx.doi.org/10.2165/00128415-201013240-00078.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

&NA;. "Mercaptopurine." Reactions Weekly &NA;, no. 1325 (October 2010): 22. http://dx.doi.org/10.2165/00128415-201013250-00080.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!